DDInter1845 DDInter1828
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces.
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Tolbutamide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Agranulocytosis {u} (Side Effect) is caused by {v} (Compound) Tolbutamide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Probenecid
Probenecid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tranylcypromine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tranylcypromine {u} (Compound) causes {v} (Side Effect) Agranulocytosis
Agranulocytosis {u} (Side Effect) is caused by {v} (Compound) Tolazamide
Tolazamide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phenelzine
Phenelzine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Fencamfamine
Fencamfamine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolbutamide
Tranylcypromine {u} (Compound) resembles {v} (Compound) Phendimetrazine
Phendimetrazine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glipizide
Glipizide {u} (Compound) resembles {v} (Compound) Tolbutamide
Tranylcypromine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tolbutamide (Compound)
Tranylcypromine (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Tolbutamide (Compound)
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Tranylcypromine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Probenecid (Compound) and Probenecid may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Tranylcypromine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound) and Glipizide (Compound) resembles Tolbutamide (Compound)
Tranylcypromine (Compound) causes Agranulocytosis (Side Effect) and Agranulocytosis (Side Effect) is caused by Tolazamide (Compound) and Tolazamide (Compound) resembles Tolbutamide (Compound)
Tranylcypromine (Compound) resembles Phenelzine (Compound) and Phenelzine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Tranylcypromine (Compound) resembles Fencamfamine (Compound) and Fencamfamine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Tranylcypromine (Compound) resembles Phendimetrazine (Compound) and Phendimetrazine may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)